Previous Article | Next Article ![]()
Infect. Immun., May 1996, 1666-1671, Vol 64, No. 5
DE Lanar, JA Tine, C de Taisne, MC Seguin, WI Cox, JP Winslow, LA Ware, EB Kauffman, D Gordon, WR Ballou, E Paoletti and JC Sadoff
NYVAC-based vaccinia virus recombinants expressing the circumsporozoite
protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model
system. Immunization of mice with a NYVAC-based CSP recombinant elicited a
high level of protection (60 to 100%). Protection did not correlate with CS
repeat-specific antibody responses and was abrogated by in vivo CD8+ T-cell
depletion. Protection was not enhanced by modification of the subcellular
localization of CSP. These results suggest the potential of poxvirus-based
vectors for the development of vaccine candidates for human malaria.
Copyright © 1996, American Society for Microbiology
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria
Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307, USA.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|